LATE STAGE TRIAL
-
AstraZeneca's COVID prevention drug cuts risk of disease in vulnerable patients
Immunocompromised people include those with blood cancer, organ transplant recipients, patients with end-stage renal disease requiring dialysis, patients receiving B-cell depleting therapy within the past year, and those taking immunosuppressive medications, it said.
-
Merck's endometrial cancer therapy fails trial
-
Cerevel's Parkinson's disease drug improves symptom control in late-stage trial
-
AstraZeneca's drug combo shows positive results in late-stage cancer trial
-
FibroGen's anemia drug fails to meet main goal in late-stage trial
-
Lilly drug slows Alzheimer's progression by 35% in trial
-
BeiGene's gastric cancer drug succeeds in late-stage trial
-
AstraZeneca says drug combo meets goal in late-stage ovarian cancer trial
Advertisement
Advertisement